Reuters logo
BUZZ-Regeneron Pharmaceuticals Inc: Study shows Eylea better than rivals
2014年10月17日 / 下午1点13分 / 3 年前

BUZZ-Regeneron Pharmaceuticals Inc: Study shows Eylea better than rivals

** Drugmaker’s shares up 7.3 pct at $365.74

** National Institutes of Health-sponsored study shows company’s eye injection Eylea more effective than rival drugs - Avastin and Lucentis - from Roche Holding AG

** Drugs were being evaluated in patients with Diabetic Macular Edema (DME), a swelling on the back of the retina that in the most severe cases can lead to blindness

** “This positive independent outcome will help further boost Eylea positioning as a superior treatment for DME compared to the competition,” Roth analyst Joseph Pantginis said

** Data also demonstrated how patients on Eylea required less-frequent injections and fewer laser treatments against those on other drugs

** Up to Thursday’s close, the stock had risen about 14 pct this year

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below